标记免疫分析与临床2024,Vol.31Issue(2) :387-392.DOI:10.11748/bjmy.issn.1006-1703.2024.02.038

抗Xa因子在高风险患者群体中抗凝给药的监测作用

A Study of Monitoring Effect of Anti-Xa Factor on Anticoagulation Administration in High-risk Patients

李雪 杨卫 李永旺 戴冬雪 马蓓洁 张静波 蔡会欣
标记免疫分析与临床2024,Vol.31Issue(2) :387-392.DOI:10.11748/bjmy.issn.1006-1703.2024.02.038

抗Xa因子在高风险患者群体中抗凝给药的监测作用

A Study of Monitoring Effect of Anti-Xa Factor on Anticoagulation Administration in High-risk Patients

李雪 1杨卫 2李永旺 2戴冬雪 2马蓓洁 2张静波 2蔡会欣2
扫码查看

作者信息

  • 1. 承德医学院研究生学院,河北 承德 067000;保定市第一中心医院,河北 保定 071000
  • 2. 保定市第一中心医院,河北 保定 071000
  • 折叠

摘要

静脉血栓栓塞症(VTE)是全世界重点关注的公共健康问题,由于其较高的发病率与致死率,国内外多项VTE防治指南提出了预防策略,但仍有VTE事件的发生.低分子肝素(LMWH)是临床上目前抗凝的首要选择,监测其抗凝疗效,可以降低血栓发生的风险.研究表明抗Xa活性水平可以很好地评估LMWH的抗凝效果,本文将对特殊人群在预防性抗凝治疗中抗Xa因子指标的作用进行综述,评估抗Xa因子监测抗凝用药的安全性和有效性.

Abstract

Venous thromboembolism(VTE)is a world-wide public health problem.Due to its high incidence rate and mortality,many prevention and treatment guidelines for VTE at home and abroad have been proposed for prevention purpose,but VTE events remain as a significant issue.Low molecular weight heparin(LMWH)is currently the primary choice for anti-coagulation in clinical practice.Monitoring its anti-coagulant efficacy can reduce the risk of thrombosis.Previous research has shown that the level of anti-Xa activity can effectively evaluate the anti-coagulant effect of LMWH,This article reviews the role of anti-Xa,an indicators in preventive anti-coagulant therapy in special populations,and evaluates the safety and effectiveness of anti-Xa for monitoring anti-coagulant therapy.

关键词

抗Xa因子/静脉血栓栓塞症/低分子肝素

Key words

Venous thromboembolism/Low molecular weight heparin

引用本文复制引用

出版年

2024
标记免疫分析与临床
中国同辐股份有限公司

标记免疫分析与临床

CSTPCD
影响因子:0.978
ISSN:1006-1703
参考文献量42
段落导航相关论文